| Title |
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy
|
|---|---|
| Published in |
Core Evidence, July 2016
|
| DOI | 10.2147/ce.s76549 |
| Pubmed ID | |
| Authors |
George A Margaritopoulos, Eirini Vasarmidi, Katerina M Antoniou |
| Abstract |
The landscape of idiopathic pulmonary fibrosis (IPF) has changed. The significant progress regarding our knowledge on the pathogenesis of the disease together with the experience achieved after a series of negative trials has led to the development of two drugs for the treatment of IPF. Both pirfenidone and nintedanib can slow significantly the rate of disease progression. They are safe with side effects that can be either prevented by close collaboration between health care professionals and patients or treated successfully when they occur, rarely leading to treatment discontinuation. However, there are still few unanswered questions regarding the application of the beneficial results of pharmaceutical trials in the general population of IPF patients. Long-term "real-life" studies are being undertaken to answer these questions. In this article, we focus on the advances that have led to the development of the antifibrotic agents with particular focus on pirfenidone. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 127 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 18% |
| Student > Ph. D. Student | 19 | 15% |
| Student > Bachelor | 16 | 13% |
| Other | 14 | 11% |
| Researcher | 11 | 9% |
| Other | 18 | 14% |
| Unknown | 26 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 24% |
| Biochemistry, Genetics and Molecular Biology | 19 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 9% |
| Chemistry | 10 | 8% |
| Agricultural and Biological Sciences | 9 | 7% |
| Other | 14 | 11% |
| Unknown | 33 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2021.
All research outputs
#1,627,135
of 25,374,917 outputs
Outputs from Core Evidence
#3
of 77 outputs
Outputs of similar age
#29,485
of 367,263 outputs
Outputs of similar age from Core Evidence
#1
of 1 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 77 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,263 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them